MIOX (myo-inositol oxygenase) is a cytoplasmic enzyme that catalyzes myo-inositol catabolism and possesses ferric iron-binding and NADP+-dependent alcohol dehydrogenase activities 1. The enzyme plays a multifaceted role in cellular redox homeostasis and metabolic regulation. Mechanistically, MIOX modulates intracellular reactive oxygen species (ROS) production and reduces levels of NADPH and glutathione (GSH), thereby regulating ferroptotic pathways 2. In ccRCC cells, MIOX overexpression inhibits autophagy to elevate ROS levels, suppressing STAT3/c-Myc-mediated epithelial-mesenchymal transition and reducing proliferation, migration, and metastatic potential 3. MIOX is significantly downregulated in ccRCC tumor epithelial cells, with low expression correlating with poor prognosis and reduced metastasis-free survival 3. Disease relevance is substantial in renal cell carcinoma, where MIOX demonstrates independent prognostic significance and serves as a potential ferroptosis-targeting therapeutic candidate 4. Conversely, MIOX upregulation promotes inflammation in infection-induced cardiac dysfunction by suppressing NLRP3 inflammasome degradation 5. MIOX elevation in serum correlates with acute kidney injury following percutaneous nephrolithotomy 6. Clinically, MIOX represents a promising biomarker for ccRCC prognosis and a therapeutic target for ferroptosis-based cancer treatment strategies 42, while its inhibition may benefit inflammatory cardiac pathologies.